[Treatment of stage D prostate cancer patients with hormones in combination with cyclophosphamide].
Eleven patients with newly diagnosed stage D prostate cancer between June, 1984 and June, 1985, were administered 300 mg/day of Honvan in 3 divided portions, 4 capsules/day of Estracyt in 2 divided portions, or 100 mg/day of Prostal in 2 divided portions was administered orally, concomitantly with large-dose intermittent treatment of 1 g/m2/3 weeks of cyclophosphamide. According to the NPCP criteria, of the 5 cases given Honvan 1 case was PR and 4 cases were stable: all 3 cases given Estracyt were stable: and in 3 cases given Prostal, 1 case was stable, 1 case had progression and 1 case dropped out. The response duration of this combination therapy was 3 to 16 months (average: 9.9 months), and obvious improvements in the subjective symptoms and performance status were noted in the cases that responded to the treatment. As for side effects, gastrointestinal symptoms were observed in 9 cases, leucopenia in 3 cases, and thrombocytopenia in 1 case. All these cases, however, were slight and transient. In 1 case, jaundice and an elevation in GOT and GPT were detected, but these changes were also temporary.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D002715:Chlormadinone Acetate / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004054:Diethylstilbestrol / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004961:Estramustine / Q000008:administration & dosage; D006728:Hormones / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D006728:Hormones; D002715:Chlormadinone Acetate; D004961:Estramustine; D004054:Diethylstilbestrol; D003520:Cyclophosphamide